Cargando…

Localized ablative immunotherapy drives de novo CD8(+) T-cell responses to poorly immunogenic tumors

BACKGROUND: Localized ablative immunotherapies hold great promise in stimulating antitumor immunity to treat metastatic and poorly immunogenic tumors. Tumor ablation is well known to release tumor antigens and danger-associated molecular patterns to stimulate T-cell immunity, but its immune stimulat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoover, Ashley R, Kaabinejadian, Saghar, Krawic, Jason R, Sun, Xiao-Hong, Naqash, Abdul Rafeh, Yin, Qian, Yang, Xinbo, Christopher Garcia, K, Davis, Mark M, Hildebrand, William H, Chen, Wei R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Oncolytic and Local Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577935/ https://www.ncbi.nlm.nih.gov/pubmed/36253002 http://dx.doi.org/10.1136/jitc-2022-004973

Ejemplares similares

In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models
por: Oba, Takaaki, et al.
Publicado: (2021)

Simple and effective bacterial-based intratumoral cancer immunotherapy
por: Carroll, Christina S E, et al.
Publicado: (2021)

Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma
por: Wang-Bishop, Lihong, et al.
Publicado: (2020)

Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity
por: Thier, Beatrice, et al.
Publicado: (2022)

Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma
por: Aiken, Taylor J, et al.
Publicado: (2022)

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
por: Jiang, Xiaoyi, et al.
Publicado: (2022)

Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice
por: Meyblum, Louis, et al.
Publicado: (2023)

Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer
por: Brito Baleeiro, Renato, et al.
Publicado: (2023)

Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy
por: Muñoz, Nina M., et al.
Publicado: (2021)

Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma
por: Morales-Molina, Alvaro, et al.
Publicado: (2021)

Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
por: Groeneveldt, Christianne, et al.
Publicado: (2020)

Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models
por: Koch, Marilin S, et al.
Publicado: (2022)

New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models
por: Lopes, Alessandra, et al.
Publicado: (2021)

Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy
por: Munoz, Luis Enrique, et al.
Publicado: (2021)

Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation
por: Alshebremi, Mohammad, et al.
Publicado: (2023)

Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy
por: Khalique, Hena, et al.
Publicado: (2021)

Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression
por: Nelson, Adam, et al.
Publicado: (2022)

Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy
por: Yang, Zaofeng, et al.
Publicado: (2022)

PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way
por: Yu, Xiaolu, et al.
Publicado: (2022)

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
por: Lee, Won Suk, et al.
Publicado: (2022)

Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis
por: Gebremeskel, Simon, et al.
Publicado: (2021)

Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
por: Zhu, Yu-Chao, et al.
Publicado: (2021)

Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3α Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity
por: Wang, Jin-Yan, et al.
Publicado: (2022)

Short-course neoadjuvant in situ vaccination for murine melanoma
por: Aiken, Taylor J, et al.
Publicado: (2022)

Intratumor childhood vaccine-specific CD4(+) T-cell recall coordinates antitumor CD8(+) T cells and eosinophils
por: Brown, Michael C, et al.
Publicado: (2023)

High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege
por: Ager, Casey R, et al.
Publicado: (2021)

Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer
por: van Vloten, Jacob P, et al.
Publicado: (2022)

Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer
por: Jhawar, Sachin R, et al.
Publicado: (2023)

Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer
por: Maslov, Diana V, et al.
Publicado: (2021)

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors
por: Rudin, Charles M, et al.
Publicado: (2023)

Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model
por: Shankara Narayanan, Jayanth S, et al.
Publicado: (2023)

Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study
por: Curti, Brendan D, et al.
Publicado: (2022)

Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression
por: Hwang, Bin-Jin, et al.
Publicado: (2022)

Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity
por: Yu, Xiaofei, et al.
Publicado: (2021)

Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy
por: Ghonime, Mohammed G, et al.
Publicado: (2021)

In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy
por: Cheng, Yinwen, et al.
Publicado: (2020)

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
por: Siu, Lillian, et al.
Publicado: (2020)

Nanoemulsion adjuvantation strategy of tumor-associated antigen therapy rephrases mucosal and immunotherapeutic signatures following intranasal vaccination
por: Huang, Chung-Hsiung, et al.
Publicado: (2020)

Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication
por: Flores, Erica B, et al.
Publicado: (2020)

Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning
por: Pol, Jonathan G, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tdqqmna2sv9ghnnu9nj8gqcjms